 Henry Galan
Concepts (501)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Fetal Growth Retardation | 45 | 2022 | 431 | 6.730 |
Why?
| | Ultrasonography, Prenatal | 31 | 2022 | 262 | 4.320 |
Why?
| | Placenta | 28 | 2022 | 554 | 3.660 |
Why?
| | Pregnancy | 94 | 2022 | 5185 | 2.600 |
Why?
| | Ultrasonography, Doppler | 16 | 2022 | 113 | 1.900 |
Why?
| | Uterine Artery | 6 | 2020 | 66 | 1.900 |
Why?
| | Sheep | 27 | 2017 | 776 | 1.780 |
Why?
| | Fetus | 21 | 2020 | 674 | 1.760 |
Why?
| | Gestational Age | 32 | 2022 | 765 | 1.660 |
Why?
| | Pregnancy, Twin | 4 | 2022 | 20 | 1.480 |
Why?
| | Meningomyelocele | 4 | 2020 | 56 | 1.360 |
Why?
| | Fetofetal Transfusion | 4 | 2022 | 20 | 1.320 |
Why?
| | Fetal Development | 3 | 2021 | 231 | 1.210 |
Why?
| | Fetal Diseases | 5 | 2017 | 193 | 1.200 |
Why?
| | Inositol | 5 | 2014 | 28 | 1.080 |
Why?
| | Fetal Weight | 5 | 2022 | 45 | 1.050 |
Why?
| | Delivery, Obstetric | 5 | 2021 | 121 | 1.040 |
Why?
| | Sorbitol | 4 | 2014 | 23 | 0.960 |
Why?
| | Nitric Oxide Synthase Type III | 6 | 2011 | 200 | 0.950 |
Why?
| | Umbilical Veins | 6 | 2009 | 68 | 0.890 |
Why?
| | Female | 98 | 2022 | 62624 | 0.880 |
Why?
| | Umbilical Arteries | 9 | 2022 | 39 | 0.870 |
Why?
| | Cerclage, Cervical | 2 | 2022 | 5 | 0.870 |
Why?
| | Infant, Newborn | 29 | 2022 | 5017 | 0.850 |
Why?
| | X-Linked Inhibitor of Apoptosis Protein | 2 | 2010 | 14 | 0.820 |
Why?
| | Uterine Cervical Incompetence | 1 | 2019 | 3 | 0.810 |
Why?
| | Altitude | 4 | 2013 | 457 | 0.770 |
Why?
| | Pre-Eclampsia | 4 | 2015 | 163 | 0.760 |
Why?
| | Pregnancy Outcome | 9 | 2020 | 340 | 0.750 |
Why?
| | Placental Insufficiency | 7 | 2017 | 94 | 0.740 |
Why?
| | Pregnancy, Animal | 4 | 2012 | 75 | 0.730 |
Why?
| | Infant, Small for Gestational Age | 4 | 2020 | 67 | 0.700 |
Why?
| | Atrioventricular Block | 1 | 2017 | 44 | 0.670 |
Why?
| | Bradycardia | 1 | 2017 | 56 | 0.670 |
Why?
| | Regional Blood Flow | 8 | 2011 | 443 | 0.660 |
Why?
| | Amniotic Fluid | 7 | 2022 | 75 | 0.660 |
Why?
| | Laser Coagulation | 1 | 2016 | 46 | 0.630 |
Why?
| | Maternal-Fetal Exchange | 8 | 2021 | 167 | 0.610 |
Why?
| | Opioid-Related Disorders | 1 | 2020 | 286 | 0.610 |
Why?
| | Birth Weight | 8 | 2017 | 411 | 0.560 |
Why?
| | Amino Acids | 4 | 2021 | 408 | 0.560 |
Why?
| | Uterus | 3 | 2011 | 205 | 0.560 |
Why?
| | Adipose Tissue | 3 | 2016 | 662 | 0.550 |
Why?
| | Body Composition | 4 | 2017 | 738 | 0.540 |
Why?
| | Disease Models, Animal | 15 | 2021 | 3892 | 0.540 |
Why?
| | Nitric Oxide Synthase | 3 | 2006 | 250 | 0.530 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 3 | 2014 | 175 | 0.520 |
Why?
| | Nitric Oxide | 7 | 2011 | 879 | 0.510 |
Why?
| | Obstetrics | 5 | 2018 | 139 | 0.510 |
Why?
| | Puerperal Disorders | 2 | 2008 | 32 | 0.510 |
Why?
| | Humans | 78 | 2022 | 112249 | 0.510 |
Why?
| | Laser-Doppler Flowmetry | 3 | 2005 | 35 | 0.500 |
Why?
| | Pulsatile Flow | 7 | 2011 | 61 | 0.490 |
Why?
| | Pregnancy Complications | 5 | 2022 | 484 | 0.470 |
Why?
| | NFATC Transcription Factors | 1 | 2012 | 83 | 0.470 |
Why?
| | Iron-Dextran Complex | 2 | 2003 | 7 | 0.450 |
Why?
| | Blood Pressure | 4 | 2017 | 1755 | 0.430 |
Why?
| | Biometry | 2 | 2008 | 68 | 0.430 |
Why?
| | Organ Size | 11 | 2015 | 500 | 0.430 |
Why?
| | Blood Flow Velocity | 6 | 2011 | 378 | 0.430 |
Why?
| | Amniocentesis | 4 | 2019 | 25 | 0.420 |
Why?
| | Ultrasonography, Doppler, Color | 1 | 2009 | 36 | 0.410 |
Why?
| | Fetal Therapies | 3 | 2019 | 35 | 0.410 |
Why?
| | Gastroschisis | 2 | 2020 | 22 | 0.410 |
Why?
| | Pregnancy Reduction, Multifetal | 2 | 2021 | 9 | 0.410 |
Why?
| | Hemodynamics | 8 | 2009 | 1097 | 0.400 |
Why?
| | Apoptosis | 5 | 2017 | 2662 | 0.400 |
Why?
| | Caspase 3 | 1 | 2010 | 256 | 0.400 |
Why?
| | Amino Acids, Essential | 1 | 2008 | 11 | 0.390 |
Why?
| | Polycythemia | 2 | 2021 | 30 | 0.390 |
Why?
| | Proto-Oncogene Proteins c-akt | 3 | 2011 | 439 | 0.380 |
Why?
| | Iliac Vein | 1 | 2008 | 7 | 0.370 |
Why?
| | Nutritional Status | 1 | 2010 | 280 | 0.370 |
Why?
| | Iliac Artery | 1 | 2008 | 35 | 0.360 |
Why?
| | Femoral Vein | 1 | 2008 | 30 | 0.360 |
Why?
| | Animals | 41 | 2021 | 35194 | 0.360 |
Why?
| | Heart Rate | 2 | 2012 | 842 | 0.360 |
Why?
| | Dystocia | 1 | 2007 | 6 | 0.360 |
Why?
| | Papio | 5 | 2021 | 98 | 0.360 |
Why?
| | Prenatal Diagnosis | 3 | 2017 | 177 | 0.350 |
Why?
| | Twins, Monozygotic | 2 | 2021 | 285 | 0.340 |
Why?
| | Retrospective Studies | 14 | 2021 | 11118 | 0.340 |
Why?
| | Protein Kinases | 1 | 2009 | 338 | 0.340 |
Why?
| | Venous Thrombosis | 1 | 2008 | 137 | 0.320 |
Why?
| | Lung | 10 | 2021 | 3586 | 0.310 |
Why?
| | Airway Obstruction | 2 | 2020 | 161 | 0.300 |
Why?
| | Premature Birth | 3 | 2022 | 216 | 0.300 |
Why?
| | Retroviridae | 2 | 2002 | 98 | 0.300 |
Why?
| | Gynecology | 2 | 2018 | 166 | 0.300 |
Why?
| | Trophoblasts | 5 | 2015 | 171 | 0.300 |
Why?
| | Fellowships and Scholarships | 2 | 2018 | 207 | 0.300 |
Why?
| | Fetoscopy | 3 | 2022 | 27 | 0.290 |
Why?
| | Transcription Factors | 2 | 2014 | 1636 | 0.290 |
Why?
| | Asphyxia | 1 | 2003 | 16 | 0.270 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 2 | 2018 | 322 | 0.270 |
Why?
| | Pregnancy Complications, Cardiovascular | 1 | 2004 | 76 | 0.270 |
Why?
| | Pregnancy Trimester, Third | 4 | 2020 | 81 | 0.270 |
Why?
| | RNA, Messenger | 7 | 2012 | 2847 | 0.260 |
Why?
| | Pregnancy Proteins | 2 | 2015 | 39 | 0.260 |
Why?
| | Adult | 24 | 2021 | 31789 | 0.260 |
Why?
| | Transduction, Genetic | 2 | 2002 | 133 | 0.250 |
Why?
| | Fever | 5 | 2009 | 308 | 0.250 |
Why?
| | Osmolar Concentration | 3 | 2014 | 230 | 0.250 |
Why?
| | Pulmonary Surfactants | 2 | 1993 | 102 | 0.250 |
Why?
| | Models, Animal | 3 | 2012 | 393 | 0.240 |
Why?
| | Uterine Cervical Diseases | 1 | 2022 | 5 | 0.240 |
Why?
| | Blood Circulation | 1 | 2002 | 36 | 0.240 |
Why?
| | Hot Temperature | 3 | 2014 | 378 | 0.240 |
Why?
| | Aspirin | 2 | 2015 | 305 | 0.240 |
Why?
| | Fetal Monitoring | 1 | 2002 | 26 | 0.240 |
Why?
| | Meconium | 1 | 2001 | 8 | 0.240 |
Why?
| | Meconium Aspiration Syndrome | 1 | 2001 | 11 | 0.240 |
Why?
| | Genetic Vectors | 2 | 2002 | 319 | 0.240 |
Why?
| | Blood Vessels | 2 | 2000 | 192 | 0.240 |
Why?
| | Diet, Protein-Restricted | 1 | 2021 | 9 | 0.230 |
Why?
| | Cervix Uteri | 1 | 2022 | 51 | 0.230 |
Why?
| | Nasopharynx | 1 | 2001 | 60 | 0.230 |
Why?
| | Amino Acid Transport System L | 1 | 2021 | 17 | 0.230 |
Why?
| | Embryonic and Fetal Development | 5 | 2002 | 101 | 0.230 |
Why?
| | Amino Acid Transport System A | 1 | 2021 | 33 | 0.230 |
Why?
| | Retrognathia | 1 | 2020 | 5 | 0.220 |
Why?
| | Micrognathism | 1 | 2020 | 8 | 0.220 |
Why?
| | Bupivacaine | 1 | 2020 | 34 | 0.220 |
Why?
| | Arm | 2 | 2016 | 97 | 0.220 |
Why?
| | Prenatal Care | 3 | 2017 | 220 | 0.220 |
Why?
| | Umbilical Cord | 5 | 2010 | 88 | 0.210 |
Why?
| | Sensitivity and Specificity | 6 | 2015 | 1926 | 0.210 |
Why?
| | Heart Diseases | 1 | 2004 | 366 | 0.210 |
Why?
| | Myometrium | 2 | 2011 | 39 | 0.210 |
Why?
| | Respiration | 4 | 2006 | 186 | 0.210 |
Why?
| | Ductus Arteriosus | 3 | 2018 | 76 | 0.210 |
Why?
| | Anesthetics, Local | 1 | 2020 | 88 | 0.210 |
Why?
| | Goats | 1 | 1999 | 30 | 0.210 |
Why?
| | Twins, Dizygotic | 1 | 2021 | 250 | 0.210 |
Why?
| | Risk Factors | 8 | 2021 | 8978 | 0.210 |
Why?
| | Respiratory Distress Syndrome, Newborn | 3 | 1999 | 99 | 0.210 |
Why?
| | Anemia | 1 | 2021 | 164 | 0.200 |
Why?
| | Leg | 2 | 2016 | 237 | 0.200 |
Why?
| | Obstetric Surgical Procedures | 1 | 2019 | 7 | 0.200 |
Why?
| | Pregnancy Trimester, Second | 3 | 2017 | 78 | 0.200 |
Why?
| | Endothelium, Vascular | 1 | 2006 | 971 | 0.190 |
Why?
| | Reference Values | 4 | 2008 | 876 | 0.190 |
Why?
| | Maternal Health | 1 | 2019 | 44 | 0.190 |
Why?
| | Pain, Postoperative | 1 | 2020 | 187 | 0.190 |
Why?
| | Tocolytic Agents | 1 | 2018 | 18 | 0.190 |
Why?
| | Hernias, Diaphragmatic, Congenital | 1 | 2021 | 160 | 0.190 |
Why?
| | Prospective Studies | 6 | 2017 | 6167 | 0.190 |
Why?
| | Indomethacin | 1 | 2018 | 86 | 0.190 |
Why?
| | Infant | 6 | 2022 | 8024 | 0.190 |
Why?
| | Internship and Residency | 2 | 2018 | 947 | 0.190 |
Why?
| | Immunohistochemistry | 4 | 2010 | 1828 | 0.180 |
Why?
| | Maternal Exposure | 1 | 2020 | 134 | 0.180 |
Why?
| | Case-Control Studies | 5 | 2021 | 3353 | 0.180 |
Why?
| | Hyaline Membrane Disease | 2 | 1997 | 21 | 0.180 |
Why?
| | Hysterotomy | 1 | 2017 | 10 | 0.180 |
Why?
| | Biological Transport | 3 | 2021 | 435 | 0.180 |
Why?
| | Colorado | 7 | 2020 | 4552 | 0.180 |
Why?
| | Cardiomyopathies | 1 | 2021 | 298 | 0.180 |
Why?
| | Antibiotic Prophylaxis | 2 | 2011 | 96 | 0.170 |
Why?
| | Duodenal Obstruction | 1 | 2017 | 7 | 0.170 |
Why?
| | Time Factors | 8 | 2019 | 7054 | 0.170 |
Why?
| | Esophageal Atresia | 1 | 2017 | 19 | 0.170 |
Why?
| | Body Mass Index | 3 | 2019 | 2076 | 0.170 |
Why?
| | Paralysis | 1 | 1997 | 66 | 0.170 |
Why?
| | Attitude | 1 | 2018 | 228 | 0.160 |
Why?
| | Lateral Ventricles | 1 | 2016 | 21 | 0.160 |
Why?
| | Placental Circulation | 3 | 2012 | 46 | 0.160 |
Why?
| | Intracranial Embolism and Thrombosis | 1 | 1995 | 5 | 0.160 |
Why?
| | Protein S Deficiency | 1 | 1995 | 7 | 0.160 |
Why?
| | Hypertension | 1 | 2005 | 1166 | 0.160 |
Why?
| | Symporters | 2 | 2014 | 60 | 0.160 |
Why?
| | Comorbidity | 1 | 2021 | 1597 | 0.160 |
Why?
| | Fetal Death | 2 | 2008 | 49 | 0.160 |
Why?
| | Caspases | 1 | 2017 | 293 | 0.150 |
Why?
| | Fetal Blood | 3 | 2008 | 267 | 0.150 |
Why?
| | Hydrocephalus | 1 | 2016 | 68 | 0.150 |
Why?
| | Mannose | 2 | 2012 | 20 | 0.150 |
Why?
| | Aldehyde Reductase | 2 | 2014 | 106 | 0.150 |
Why?
| | Choriocarcinoma | 1 | 2014 | 6 | 0.150 |
Why?
| | Blotting, Western | 4 | 2011 | 1316 | 0.150 |
Why?
| | Coronary Circulation | 1 | 2015 | 170 | 0.140 |
Why?
| | Metformin | 1 | 2018 | 281 | 0.140 |
Why?
| | Fetal Heart | 1 | 2015 | 57 | 0.140 |
Why?
| | Cohort Studies | 4 | 2020 | 4937 | 0.140 |
Why?
| | MicroRNAs | 1 | 2021 | 626 | 0.140 |
Why?
| | Sheep Diseases | 1 | 2014 | 6 | 0.140 |
Why?
| | Diabetes, Gestational | 1 | 2018 | 263 | 0.140 |
Why?
| | Pilot Projects | 3 | 2020 | 1406 | 0.140 |
Why?
| | HSP27 Heat-Shock Proteins | 1 | 2014 | 14 | 0.140 |
Why?
| | Uterine Neoplasms | 1 | 2014 | 58 | 0.140 |
Why?
| | Saline Solution, Hypertonic | 1 | 2014 | 68 | 0.140 |
Why?
| | Bronchogenic Cyst | 1 | 2013 | 5 | 0.140 |
Why?
| | Caloric Restriction | 1 | 2015 | 120 | 0.140 |
Why?
| | Young Adult | 6 | 2021 | 10899 | 0.140 |
Why?
| | Regression Analysis | 3 | 2008 | 1136 | 0.130 |
Why?
| | Calcium | 2 | 2011 | 1215 | 0.130 |
Why?
| | Body Weights and Measures | 1 | 2013 | 40 | 0.130 |
Why?
| | Analgesics, Opioid | 1 | 2020 | 672 | 0.130 |
Why?
| | Femur | 3 | 2008 | 179 | 0.130 |
Why?
| | Down-Regulation | 3 | 2021 | 681 | 0.130 |
Why?
| | Umbilicus | 1 | 2013 | 13 | 0.130 |
Why?
| | Fatty Alcohols | 1 | 1992 | 4 | 0.130 |
Why?
| | Coronary Vessels | 1 | 2015 | 283 | 0.130 |
Why?
| | Phosphorylcholine | 1 | 1992 | 18 | 0.130 |
Why?
| | Rabbits | 3 | 2003 | 816 | 0.130 |
Why?
| | Amnion | 1 | 1992 | 28 | 0.120 |
Why?
| | Longitudinal Studies | 3 | 2013 | 2673 | 0.120 |
Why?
| | Ultrasonography | 2 | 2022 | 764 | 0.120 |
Why?
| | Gene Expression Regulation, Developmental | 3 | 2010 | 892 | 0.120 |
Why?
| | NADP | 1 | 2012 | 67 | 0.120 |
Why?
| | Estradiol | 3 | 2000 | 450 | 0.120 |
Why?
| | Muscle, Skeletal | 1 | 2001 | 1406 | 0.120 |
Why?
| | Calcium Signaling | 2 | 2011 | 236 | 0.120 |
Why?
| | Signal Transduction | 4 | 2011 | 4914 | 0.120 |
Why?
| | Isotope Labeling | 1 | 2012 | 92 | 0.120 |
Why?
| | Cesarean Section | 2 | 2012 | 147 | 0.110 |
Why?
| | Animals, Newborn | 5 | 2000 | 868 | 0.110 |
Why?
| | Pregnancy Trimesters | 1 | 2010 | 13 | 0.110 |
Why?
| | Blood Volume | 1 | 2011 | 66 | 0.110 |
Why?
| | Pregnancy-Associated Plasma Protein-A | 1 | 2010 | 16 | 0.110 |
Why?
| | Keratin-18 | 1 | 2010 | 12 | 0.110 |
Why?
| | Abdomen | 2 | 2003 | 123 | 0.110 |
Why?
| | Galectins | 1 | 2010 | 19 | 0.110 |
Why?
| | Chorionic Villi | 1 | 2010 | 16 | 0.110 |
Why?
| | Practice Guidelines as Topic | 2 | 2018 | 1526 | 0.110 |
Why?
| | Infant, Premature | 2 | 2012 | 448 | 0.110 |
Why?
| | Probability | 2 | 2001 | 339 | 0.110 |
Why?
| | Clinical Competence | 1 | 2018 | 904 | 0.110 |
Why?
| | Carbohydrate Metabolism | 1 | 2010 | 59 | 0.110 |
Why?
| | Carbohydrates | 1 | 2010 | 64 | 0.110 |
Why?
| | Calcium Channels | 1 | 2011 | 155 | 0.100 |
Why?
| | Term Birth | 1 | 2009 | 16 | 0.100 |
Why?
| | Hypoglycemic Agents | 1 | 2018 | 1018 | 0.100 |
Why?
| | TRPC Cation Channels | 1 | 2009 | 11 | 0.100 |
Why?
| | Diagnostic Techniques, Cardiovascular | 1 | 2009 | 17 | 0.100 |
Why?
| | Oxygen | 4 | 2008 | 881 | 0.100 |
Why?
| | Cell Hypoxia | 1 | 2011 | 238 | 0.100 |
Why?
| | Magnetic Resonance Imaging | 3 | 2016 | 3017 | 0.100 |
Why?
| | Diglycerides | 1 | 2009 | 62 | 0.100 |
Why?
| | Middle Cerebral Artery | 1 | 2009 | 28 | 0.100 |
Why?
| | High-Frequency Ventilation | 2 | 1999 | 46 | 0.100 |
Why?
| | Hyperthermia, Induced | 1 | 2010 | 79 | 0.100 |
Why?
| | Cordocentesis | 1 | 2008 | 1 | 0.100 |
Why?
| | Angiography | 1 | 2009 | 157 | 0.100 |
Why?
| | Crown-Rump Length | 1 | 2008 | 4 | 0.090 |
Why?
| | Biomarkers | 3 | 2021 | 3464 | 0.090 |
Why?
| | Endoplasmic Reticulum | 1 | 2011 | 247 | 0.090 |
Why?
| | Endothelin-1 | 2 | 2008 | 166 | 0.090 |
Why?
| | Placenta Diseases | 1 | 2008 | 13 | 0.090 |
Why?
| | Fluorocarbons | 2 | 1999 | 72 | 0.090 |
Why?
| | Enterocolitis, Necrotizing | 1 | 2008 | 21 | 0.090 |
Why?
| | Blood Gas Analysis | 1 | 2008 | 88 | 0.090 |
Why?
| | Birth Injuries | 1 | 2007 | 10 | 0.090 |
Why?
| | Foot | 1 | 2008 | 100 | 0.090 |
Why?
| | Polyethylene Glycols | 1 | 1992 | 581 | 0.090 |
Why?
| | Shoulder | 1 | 2007 | 70 | 0.080 |
Why?
| | Syndrome | 1 | 2008 | 342 | 0.080 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2009 | 352 | 0.080 |
Why?
| | Pulmonary Circulation | 2 | 2000 | 467 | 0.080 |
Why?
| | Sheep, Domestic | 1 | 2006 | 33 | 0.080 |
Why?
| | Glucose Transporter Type 4 | 1 | 2006 | 41 | 0.080 |
Why?
| | Body Weight | 3 | 2006 | 1016 | 0.080 |
Why?
| | Glucose Transporter Type 1 | 1 | 2006 | 48 | 0.080 |
Why?
| | Fetal Hypoxia | 1 | 2006 | 45 | 0.080 |
Why?
| | Infant, Premature, Diseases | 1 | 2007 | 88 | 0.080 |
Why?
| | Polymers | 1 | 2010 | 472 | 0.080 |
Why?
| | Risk | 1 | 2009 | 944 | 0.080 |
Why?
| | Biophysics | 1 | 2006 | 74 | 0.080 |
Why?
| | Vasodilation | 2 | 2000 | 472 | 0.080 |
Why?
| | Obesity | 1 | 2019 | 2602 | 0.080 |
Why?
| | Receptors, Growth Factor | 2 | 2002 | 58 | 0.080 |
Why?
| | Imaging, Three-Dimensional | 1 | 2009 | 548 | 0.070 |
Why?
| | Echocardiography | 2 | 2021 | 636 | 0.070 |
Why?
| | Models, Theoretical | 1 | 2009 | 608 | 0.070 |
Why?
| | Labor, Obstetric | 1 | 2004 | 50 | 0.070 |
Why?
| | Body Size | 1 | 2004 | 97 | 0.070 |
Why?
| | Potassium Chloride | 1 | 2003 | 52 | 0.070 |
Why?
| | Self Report | 2 | 2018 | 677 | 0.070 |
Why?
| | Heat-Shock Proteins | 2 | 2014 | 146 | 0.070 |
Why?
| | Fetal Movement | 2 | 2006 | 7 | 0.060 |
Why?
| | Vascular Endothelial Growth Factor A | 2 | 2003 | 509 | 0.060 |
Why?
| | Cerebral Palsy | 1 | 2004 | 64 | 0.060 |
Why?
| | Cardiovascular Agents | 1 | 2004 | 127 | 0.060 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 1 | 2003 | 104 | 0.060 |
Why?
| | Cells, Cultured | 4 | 2014 | 4413 | 0.060 |
Why?
| | In Situ Nick-End Labeling | 2 | 2014 | 138 | 0.060 |
Why?
| | beta-Galactosidase | 1 | 2002 | 85 | 0.060 |
Why?
| | Up-Regulation | 1 | 2006 | 973 | 0.060 |
Why?
| | Brain Diseases | 1 | 2004 | 156 | 0.060 |
Why?
| | Bone and Bones | 1 | 2004 | 251 | 0.060 |
Why?
| | Apgar Score | 1 | 2001 | 14 | 0.060 |
Why?
| | Polymerase Chain Reaction | 2 | 2002 | 1099 | 0.060 |
Why?
| | Laparoscopy | 2 | 1997 | 383 | 0.060 |
Why?
| | Endothelial Growth Factors | 1 | 2002 | 72 | 0.060 |
Why?
| | Face | 1 | 2003 | 175 | 0.060 |
Why?
| | Constriction | 2 | 2018 | 51 | 0.060 |
Why?
| | Light Coagulation | 1 | 2021 | 8 | 0.060 |
Why?
| | Italy | 1 | 2001 | 89 | 0.060 |
Why?
| | Perineum | 1 | 2001 | 29 | 0.060 |
Why?
| | Lymphokines | 1 | 2002 | 146 | 0.060 |
Why?
| | Suction | 1 | 2001 | 31 | 0.060 |
Why?
| | Treatment Outcome | 4 | 2019 | 8944 | 0.060 |
Why?
| | Endpoint Determination | 1 | 2001 | 69 | 0.060 |
Why?
| | Lung Volume Measurements | 1 | 2021 | 41 | 0.060 |
Why?
| | Algorithms | 1 | 2009 | 1548 | 0.060 |
Why?
| | Protein Biosynthesis | 1 | 2003 | 406 | 0.050 |
Why?
| | Drainage | 1 | 2021 | 147 | 0.050 |
Why?
| | Receptors, Cell Surface | 1 | 2003 | 401 | 0.050 |
Why?
| | Gene Transfer Techniques | 1 | 2001 | 154 | 0.050 |
Why?
| | Airway Management | 1 | 2020 | 44 | 0.050 |
Why?
| | Gastrostomy | 1 | 2021 | 88 | 0.050 |
Why?
| | Oxygen Consumption | 1 | 2003 | 663 | 0.050 |
Why?
| | Predictive Value of Tests | 3 | 2015 | 2021 | 0.050 |
Why?
| | Myocardium | 1 | 2006 | 1084 | 0.050 |
Why?
| | Gas Chromatography-Mass Spectrometry | 1 | 2020 | 152 | 0.050 |
Why?
| | Maternal Age | 1 | 2020 | 121 | 0.050 |
Why?
| | Cluster Analysis | 1 | 2021 | 491 | 0.050 |
Why?
| | Parietal Bone | 1 | 1999 | 10 | 0.050 |
Why?
| | Perinatal Death | 1 | 2019 | 16 | 0.050 |
Why?
| | Diffusion | 1 | 1999 | 125 | 0.050 |
Why?
| | Ventriculoperitoneal Shunt | 1 | 2019 | 30 | 0.050 |
Why?
| | Maternal Nutritional Physiological Phenomena | 1 | 2021 | 163 | 0.050 |
Why?
| | Cigarette Smoking | 1 | 2020 | 70 | 0.050 |
Why?
| | Arteries | 1 | 2000 | 231 | 0.050 |
Why?
| | Insulin | 2 | 2006 | 2167 | 0.050 |
Why?
| | Anthropometry | 1 | 1999 | 197 | 0.050 |
Why?
| | Male | 6 | 2012 | 60715 | 0.050 |
Why?
| | Pulmonary Artery | 3 | 2000 | 1073 | 0.050 |
Why?
| | Enteral Nutrition | 1 | 2019 | 154 | 0.040 |
Why?
| | Linear Models | 2 | 2017 | 909 | 0.040 |
Why?
| | Pancuronium | 1 | 1997 | 5 | 0.040 |
Why?
| | Neuromuscular Depolarizing Agents | 1 | 1997 | 4 | 0.040 |
Why?
| | Respiration, Artificial | 2 | 1999 | 547 | 0.040 |
Why?
| | Tibia | 1 | 1999 | 169 | 0.040 |
Why?
| | Phosphorylation | 2 | 2014 | 1740 | 0.040 |
Why?
| | Polyhydramnios | 1 | 2017 | 10 | 0.040 |
Why?
| | Hypertension, Pulmonary | 2 | 2000 | 1651 | 0.040 |
Why?
| | Intestinal Atresia | 1 | 2017 | 12 | 0.040 |
Why?
| | Bronchodilator Agents | 1 | 1999 | 249 | 0.040 |
Why?
| | Obstetric Labor, Premature | 1 | 1997 | 44 | 0.040 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 3 | 2007 | 1125 | 0.040 |
Why?
| | Injections, Intramuscular | 1 | 1997 | 127 | 0.040 |
Why?
| | Endothelin Receptor Antagonists | 1 | 1997 | 64 | 0.040 |
Why?
| | Cross-Sectional Studies | 2 | 2004 | 4207 | 0.040 |
Why?
| | Follow-Up Studies | 2 | 2017 | 4887 | 0.040 |
Why?
| | Statistics, Nonparametric | 1 | 1998 | 463 | 0.040 |
Why?
| | Genetic Counseling | 1 | 2017 | 66 | 0.040 |
Why?
| | Pulmonary Edema | 1 | 1997 | 159 | 0.040 |
Why?
| | United States | 3 | 2018 | 12170 | 0.040 |
Why?
| | Capillary Permeability | 1 | 1997 | 166 | 0.040 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2022 | 1130 | 0.040 |
Why?
| | Administration, Inhalation | 4 | 1999 | 645 | 0.040 |
Why?
| | Length of Stay | 1 | 2001 | 1057 | 0.040 |
Why?
| | Blood Pressure Determination | 1 | 2017 | 127 | 0.040 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2018 | 2226 | 0.040 |
Why?
| | Excitatory Amino Acids | 1 | 2015 | 12 | 0.040 |
Why?
| | Biological Transport, Active | 1 | 2015 | 77 | 0.040 |
Why?
| | Placenta Growth Factor | 1 | 2015 | 19 | 0.040 |
Why?
| | Insufflation | 1 | 1995 | 12 | 0.040 |
Why?
| | Transport Vesicles | 1 | 2015 | 19 | 0.040 |
Why?
| | Bone Marrow Transplantation | 1 | 1997 | 291 | 0.040 |
Why?
| | Saimiri | 1 | 1995 | 14 | 0.040 |
Why?
| | Uterine Prolapse | 1 | 1995 | 15 | 0.040 |
Why?
| | Urethral Diseases | 1 | 1995 | 12 | 0.040 |
Why?
| | Carbon Dioxide | 2 | 1995 | 246 | 0.040 |
Why?
| | Proteins | 1 | 2002 | 992 | 0.040 |
Why?
| | Twins | 1 | 2017 | 289 | 0.040 |
Why?
| | Genetic Therapy | 1 | 1997 | 277 | 0.040 |
Why?
| | Aorta | 1 | 1998 | 404 | 0.040 |
Why?
| | Analysis of Variance | 2 | 2000 | 1517 | 0.040 |
Why?
| | Neutrophils | 2 | 1999 | 1322 | 0.030 |
Why?
| | DNA Fragmentation | 1 | 2014 | 62 | 0.030 |
Why?
| | Societies, Medical | 1 | 2018 | 764 | 0.030 |
Why?
| | Pregnancy in Diabetics | 1 | 1995 | 88 | 0.030 |
Why?
| | Health Status | 1 | 2019 | 769 | 0.030 |
Why?
| | Thoracotomy | 1 | 2013 | 88 | 0.030 |
Why?
| | Program Evaluation | 1 | 2018 | 859 | 0.030 |
Why?
| | Surveys and Questionnaires | 3 | 2018 | 4549 | 0.030 |
Why?
| | Molecular Chaperones | 1 | 2014 | 175 | 0.030 |
Why?
| | Severity of Illness Index | 1 | 2021 | 2817 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2017 | 1599 | 0.030 |
Why?
| | Hydrogen | 1 | 2012 | 69 | 0.030 |
Why?
| | In Vitro Techniques | 1 | 2014 | 1243 | 0.030 |
Why?
| | Injections | 1 | 1992 | 164 | 0.030 |
Why?
| | Carbon Isotopes | 1 | 2012 | 119 | 0.030 |
Why?
| | Registries | 1 | 2020 | 1805 | 0.030 |
Why?
| | Drug Combinations | 1 | 1992 | 295 | 0.030 |
Why?
| | Heart Rate, Fetal | 2 | 2006 | 33 | 0.030 |
Why?
| | Respiratory Function Tests | 1 | 1993 | 593 | 0.030 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 1997 | 569 | 0.030 |
Why?
| | Logistic Models | 1 | 2017 | 2049 | 0.030 |
Why?
| | Anticoagulants | 1 | 1995 | 532 | 0.030 |
Why?
| | Myo-Inositol-1-Phosphate Synthase | 1 | 2010 | 2 | 0.030 |
Why?
| | Double-Blind Method | 1 | 2015 | 1670 | 0.030 |
Why?
| | Radiography | 1 | 1993 | 828 | 0.030 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 1 | 2011 | 158 | 0.030 |
Why?
| | Gene Silencing | 1 | 2011 | 182 | 0.030 |
Why?
| | TRPC6 Cation Channel | 1 | 2009 | 1 | 0.030 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 1 | 2011 | 190 | 0.030 |
Why?
| | Intracellular Space | 1 | 2009 | 81 | 0.030 |
Why?
| | Efficiency | 1 | 2009 | 97 | 0.020 |
Why?
| | Risk Assessment | 1 | 2019 | 3137 | 0.020 |
Why?
| | Ultrasonography, Doppler, Pulsed | 1 | 2008 | 9 | 0.020 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2011 | 218 | 0.020 |
Why?
| | Sodium | 1 | 2009 | 203 | 0.020 |
Why?
| | Fructose | 1 | 2010 | 189 | 0.020 |
Why?
| | Pulmonary Gas Exchange | 2 | 1999 | 135 | 0.020 |
Why?
| | Postoperative Complications | 1 | 2019 | 2095 | 0.020 |
Why?
| | Head | 1 | 2008 | 77 | 0.020 |
Why?
| | Adolescent | 3 | 2017 | 18577 | 0.020 |
Why?
| | RNA, Small Interfering | 1 | 2009 | 605 | 0.020 |
Why?
| | Cell Culture Techniques | 1 | 2009 | 361 | 0.020 |
Why?
| | Partial Pressure | 1 | 2006 | 34 | 0.020 |
Why?
| | Heating | 1 | 2006 | 19 | 0.020 |
Why?
| | Insulin Receptor Substrate Proteins | 1 | 2006 | 58 | 0.020 |
Why?
| | Glycogen | 1 | 2006 | 68 | 0.020 |
Why?
| | Receptor, Insulin | 1 | 2006 | 106 | 0.020 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2007 | 329 | 0.020 |
Why?
| | Endothelial Cells | 1 | 2011 | 641 | 0.020 |
Why?
| | Body Temperature | 1 | 2006 | 280 | 0.020 |
Why?
| | Forecasting | 1 | 2008 | 399 | 0.020 |
Why?
| | Gene Expression | 1 | 2011 | 1578 | 0.020 |
Why?
| | Liver | 2 | 2010 | 1859 | 0.020 |
Why?
| | Lactic Acid | 1 | 2006 | 300 | 0.020 |
Why?
| | Sequence Analysis, DNA | 1 | 2007 | 797 | 0.020 |
Why?
| | Hospitals, University | 1 | 2004 | 195 | 0.020 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2006 | 350 | 0.020 |
Why?
| | Nuclease Protection Assays | 1 | 2003 | 8 | 0.020 |
Why?
| | Phosphoproteins | 1 | 2006 | 335 | 0.020 |
Why?
| | Acid-Base Equilibrium | 1 | 2003 | 30 | 0.020 |
Why?
| | Drinking | 1 | 2003 | 49 | 0.020 |
Why?
| | Blotting, Northern | 1 | 2003 | 226 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor Receptor-1 | 1 | 2003 | 64 | 0.020 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2006 | 415 | 0.020 |
Why?
| | Terminology as Topic | 1 | 2004 | 227 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 1 | 2003 | 86 | 0.020 |
Why?
| | Respiratory Mechanics | 1 | 2003 | 79 | 0.020 |
Why?
| | Child | 2 | 2020 | 17357 | 0.020 |
Why?
| | Angiogenesis Inducing Agents | 1 | 2002 | 23 | 0.020 |
Why?
| | Galactosides | 1 | 2001 | 6 | 0.010 |
Why?
| | Vascular Endothelial Growth Factors | 1 | 2002 | 81 | 0.010 |
Why?
| | Placentation | 1 | 2002 | 48 | 0.010 |
Why?
| | Lac Operon | 1 | 2001 | 51 | 0.010 |
Why?
| | Macaca | 1 | 2001 | 72 | 0.010 |
Why?
| | 3T3 Cells | 1 | 2001 | 161 | 0.010 |
Why?
| | Stomach | 1 | 2001 | 91 | 0.010 |
Why?
| | Microcirculation | 1 | 2002 | 165 | 0.010 |
Why?
| | Morphogenesis | 1 | 2002 | 169 | 0.010 |
Why?
| | Glucose | 1 | 2006 | 866 | 0.010 |
Why?
| | Transgenes | 1 | 2001 | 191 | 0.010 |
Why?
| | Gene Expression Regulation | 1 | 2011 | 2628 | 0.010 |
Why?
| | Neovascularization, Physiologic | 1 | 2002 | 198 | 0.010 |
Why?
| | Ligation | 1 | 2000 | 83 | 0.010 |
Why?
| | Species Specificity | 1 | 2002 | 649 | 0.010 |
Why?
| | Physical Stimulation | 1 | 2000 | 113 | 0.010 |
Why?
| | Trachea | 1 | 2001 | 228 | 0.010 |
Why?
| | Hydrocarbons, Brominated | 1 | 1999 | 6 | 0.010 |
Why?
| | Hypertrophy, Right Ventricular | 1 | 2000 | 124 | 0.010 |
Why?
| | Esophagus | 1 | 2001 | 244 | 0.010 |
Why?
| | Muscle, Smooth | 1 | 2000 | 141 | 0.010 |
Why?
| | Indoles | 1 | 2001 | 356 | 0.010 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 1995 | 3262 | 0.010 |
Why?
| | Receptor, Endothelin A | 1 | 1997 | 61 | 0.010 |
Why?
| | Blood Glucose | 1 | 2006 | 1908 | 0.010 |
Why?
| | Drug Evaluation, Preclinical | 1 | 1997 | 191 | 0.010 |
Why?
| | Leukocyte Count | 1 | 1997 | 325 | 0.010 |
Why?
| | Acidosis, Respiratory | 1 | 1995 | 2 | 0.010 |
Why?
| | Postoperative Period | 1 | 1997 | 287 | 0.010 |
Why?
| | Catheterization, Swan-Ganz | 1 | 1995 | 10 | 0.010 |
Why?
| | Central Venous Pressure | 1 | 1995 | 13 | 0.010 |
Why?
| | Cardiomegaly | 1 | 1997 | 172 | 0.010 |
Why?
| | Prolapse | 1 | 1995 | 4 | 0.010 |
Why?
| | Anesthesia, General | 1 | 1995 | 46 | 0.010 |
Why?
| | Tidal Volume | 1 | 1995 | 82 | 0.010 |
Why?
| | General Surgery | 1 | 1997 | 122 | 0.010 |
Why?
| | Pulmonary Wedge Pressure | 1 | 1995 | 70 | 0.010 |
Why?
| | Vulva | 1 | 1995 | 20 | 0.010 |
Why?
| | Cardiac Output | 1 | 1995 | 159 | 0.010 |
Why?
| | Membrane Proteins | 1 | 2002 | 1091 | 0.010 |
Why?
| | Peptides, Cyclic | 1 | 1997 | 258 | 0.010 |
Why?
| | Cell Line | 1 | 2001 | 3013 | 0.010 |
Why?
| | Vasodilator Agents | 1 | 1997 | 323 | 0.010 |
Why?
| | Safety | 1 | 1997 | 319 | 0.010 |
Why?
| | Catheterization, Peripheral | 1 | 1995 | 86 | 0.010 |
Why?
| | Pressure | 1 | 1995 | 257 | 0.010 |
Why?
| | Vascular Resistance | 1 | 1995 | 397 | 0.010 |
Why?
| | Vagina | 1 | 1995 | 163 | 0.010 |
Why?
| | Oxazoles | 1 | 1971 | 36 | 0.010 |
Why?
| | Penicillins | 1 | 1971 | 57 | 0.010 |
Why?
| | Databases, Factual | 1 | 1997 | 1184 | 0.010 |
Why?
| | Chronic Disease | 1 | 1997 | 1666 | 0.010 |
Why?
| | Leukocytes | 1 | 1971 | 301 | 0.010 |
Why?
| | Respiratory Tract Infections | 1 | 1971 | 258 | 0.010 |
Why?
| | Mice | 1 | 2001 | 15510 | 0.000 |
Why?
| | Middle Aged | 1 | 2006 | 28676 | 0.000 |
Why?
| | Kidney | 1 | 1971 | 1187 | 0.000 |
Why?
| | Dicloxacillin | 1 | 1971 | 1 | 0.000 |
Why?
| | Evaluation Studies as Topic | 1 | 1971 | 226 | 0.000 |
Why?
| | Imidazoles | 1 | 1971 | 259 | 0.000 |
Why?
| | Administration, Oral | 1 | 1971 | 800 | 0.000 |
Why?
| | Child, Preschool | 1 | 1971 | 9655 | 0.000 |
Why?
|
|
Galan's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|